What Matrix Treats: Main Uses and Benefits

Matrix is commonly applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms, which includes both symptoms related to inflammatory or irritative states and symptoms associated with acute or episodic changes. It is relevant for easing symptoms such as joint pain, swelling, muscle aches, headache, and fever.

---

Easing Discomfort and Supporting Stability

The medication provides short-term symptomatic assistance generally used in situations involving mild to moderate intensity discomfort, such as pain following minor surgical or dental procedures, or the cramping associated with primary dysmenorrhea. It helps reduce the overall burden of these manifestations and supports general well-being during symptomatic phases. It is applicable for managing symptoms that cluster into patterns requiring supportive management, including those linked to Osteoarthritis and Rheumatoid Arthritis.

Quick Fact: Used for managing Joint Stiffness and Fever

The medication is commonly utilized to assist with coping during difficult episodes by easing distress. This supportive role assists with maintaining functional stability during periods of discomfort and helps address symptoms related to systemic imbalance, such as elevated body temperature associated with the common cold or flu.

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Matrix?

The official population eligibility for Matrix (Ibuprofen sustained-release tablet) is defined by age, organ health, and physiological status, as outlined in government regulatory documents.

Eligibility scope	Official Regulatory Status
Populations for whom use is allowed	Adults and adolescents weighing ≥ 40 kg (generally 12 years and above).
Populations for whom use is not recommended	Children under 12 years of age or those under 40 kg; women who are attempting to conceive.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Ibuprofen or other NSAIDs (e.g., aspirin); patients with active/recurrent peptic ulcer/haemorrhage; Severe Heart Failure, Severe Renal Failure, or Severe Hepatic Failure; and those undergoing treatment for peri-operative pain in CABG surgery.

---

Age- and Condition-Specific Eligibility

Age-related eligibility rules: Use is not established in children under 12 years of age for this formulation. The elderly are at an increased risk of serious adverse reactions and must use caution.

Pregnancy and lactation eligibility status: The medicine is contraindicated during the third trimester of pregnancy (after 30 weeks). Use must be limited between 20 and 30 weeks of pregnancy. Ibuprofen appears in breast milk in very low concentrations, and its use is generally considered compatible with lactation.

Condition-specific eligibility rules: Patients with mild to moderate renal or hepatic impairment require close monitoring and restricted dosing. Individuals with existing hypertension or CV disease risk factors must use the lowest effective dose for the shortest duration possible.

---

Connection to the overall eligibility profile: Regulatory documents define eligibility for Matrix by establishing clear, non-negotiable prohibitions, particularly related to severe organ failure, gastrointestinal bleeding, and late-stage pregnancy (contraindications). For other populations, use is permitted unless a specific limitation exists, such as a minimum age threshold or the need for close monitoring due to pre-existing conditions.

Interactions with other medicines and products

Regulatory documents define specific constraints for co-administration of Matrix (Ibuprofen) with other substances, classified by the official risk profile.

Contraindications and Restrictions

Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including other Ibuprofen-containing products, is formally contraindicated due to an unacceptable, additive risk of serious gastrointestinal and renal adverse events. This prohibition extends to Aspirin when used at anti-inflammatory or analgesic doses.

Official Interaction Statements

Substance Category	Officially Documented Effect
Anticoagulants (e.g., Warfarin)	Increased risk of serious bleeding due to additive pharmacodynamic effects.
Lithium, Methotrexate	Increased plasma concentrations due to a reduction in renal clearance.
Diuretics / ACE Inhibitors	Reduced efficacy of these medicines and an increased risk of acute renal failure (nephrotoxicity).
CYP2C9 Inhibitors (e.g., Fluconazole)	Increased systemic exposure of Ibuprofen due to reduced metabolic clearance.
Alcohol	Increased risk of gastrointestinal bleeding.

Timing Requirements

A mandatory timing separation is required when co-administering with low-dose Aspirin (for cardiac prophylaxis). Official regulatory guidance requires Matrix to be administered either 8 hours before or 30 minutes after the immediate-release low-dose Aspirin dose to prevent interference with its antiplatelet effect.

Blocking Enzyme Activity: The Core Mechanism

The mechanism of Ibuprofen involves non-selective competitive inhibition of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). By reversibly binding to the active site of these enzymes, the molecule prevents them from converting their substrate, arachidonic acid, thereby halting the synthesis of crucial biological messengers known as prostaglandins.

---

Pathway Modulation: Dampening Nociception and Inflammation

The resulting suppression of prostaglandin synthesis directly influences multiple physiological processes. Peripherally, the reduction in PGE2 diminishes the sensitization of nociceptors (pain receptors), decreasing the transmission of nociceptive signals to the central nervous system. This action involves mitigating the role of prostaglandins in promoting local tissue swelling and vascular permeability.

---

Central Action: Adjusting Thermoregulation

The drug's mechanism also engages a central action within the brain's hypothalamus. Here, the blockade of PGE2 synthesis causes a reversal of the body's pathologically elevated temperature set point, leading to increased heat loss and facilitating a reduction in core temperature. This dual action—peripheral modulation of nociception and central adjustment of thermoregulation—demonstrates the mechanism's comprehensive scope.

How to Use Matrix

Matrix is an oral medication administered as a sustained-release tablet and is intended exclusively for short-term use. Its use is governed by the principle of administering the lowest effective dose for the shortest possible duration necessary to manage symptoms, following established principles for Nonsteroidal Anti-inflammatory Drugs.

The dosage regimen is determined by the tablet’s modified-release characteristic. For the sustained-release form, the medication is typically taken once every 12 hours, and administration is strictly limited to two doses in a 24-hour period. The tablet must be swallowed whole with water and must not be crushed, chewed, split, or dissolved, as altering the tablet structure compromises the controlled release of Ibuprofen over the 12-hour interval. To minimize potential gastrointestinal discomfort, the medication may be administered with food or a glass of milk.

Prescription-level use of the active ingredient, Ibuprofen, has a strict maximum daily dose of 3200 mg.

Usage Constraint	Official Requirement
Administration Route	Oral administration only.
Tablet Integrity	Must be swallowed whole.
Dosing Frequency	Typically once every 12 hours.
Maximum Limit	3200 mg total Ibuprofen daily (prescription maximum).
Duration	Limited to short-term use.

Population-Specific Usage:

Dosing requires caution and close monitoring for certain patient populations. For older adults and patients with diagnosed hepatic or renal impairment, the dosage should be kept as low as possible and treatment duration should be strictly limited. Standard administration emphasizes that the integrity of the controlled-release system is central to the use of Matrix.

Research Evidence / Overview of Studies for Matrix

Evidence for the Use in Osteoarthritis and Rheumatoid Arthritis

Research examining Ibuprofen’s profile in conditions characterized by functional limitations and periods of heightened symptoms, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA), has primarily focused on short-term and intermediate-term randomized controlled trials (RCTs). These studies were applied in research exploring how symptoms change over time in adult patients diagnosed with these conditions. Researchers monitored outcomes related to patient-reported discomfort and activity level, using tools like patient-reported scores to measure scores related to pain intensity, joint stiffness, and activity level over defined time intervals, typically lasting a few weeks to a few months.

Evidence for the Management of Acute Pain

This section describes the research base, primarily from Short-term and Ultra-short-term RCTs, that has examined the formulation in research scenarios involving acute discomfort, such as pain following minor surgical procedures like dental extraction, and the discomfort associated with primary dysmenorrhea (menstrual cramping). This research involved trials designed to assess short-term or episodic symptom patterns. For acute episodes, studies monitored outcomes describing episodic or acute changes and measuring the time profile of measured changes.

Long-Term Research and Follow-up Durations

Most clinical trials specifically studying the efficacy of Ibuprofen sustained-release in conditions characterized by fluctuating or episodic manifestations, like the chronic joint diseases, have had limited follow-up durations, often concluding after three months or less. This means that while studies describe what has been observed so far regarding short-term symptomatic change, the long-term effects of this specific formulation are not fully established through dedicated, multi-year clinical trials. Information on durability is often inferred from the broader evidence landscape for the entire Ibuprofen class.

Gaps and Uncertainties in the Evidence Base

Key limitations include the modest sample sizes of many pharmacokinetic trials and the limited information for long-term outcomes across all indications. Furthermore, comparative evidence is lacking in large studies designed to test and show whether the sustained-release formulation provides measurable different results than the standard, immediate-release Ibuprofen for all indications. Research continues to explore these uncertainties and aims to better document the long-term patterns of use across various populations.

Key Studies & References

1. Evidence-based clinical practice guideline on the use of NSAIDs in treating adult patients with osteoarthritis
2. NICE Guideline: Rheumatoid arthritis in adults: management

Common questions about Matrix (FAQ)

Q: What is the main reason doctors prescribe Matrix?

Official documents define the approved uses, known as Indications. For this medicine, these typically include the symptomatic management of chronic joint issues like Osteoarthritis and Rheumatoid Arthritis, as well as acute discomfort like Primary Dysmenorrhea (menstrual cramps).

Q: Is Matrix the same kind of medicine as [similar drug name]? What's the difference?

Matrix is a sustained-release formulation of the active ingredient Ibuprofen, placing it in the NSAID (Nonsteroidal Anti-inflammatory Drug) class. The sustained-release system is the key factual difference, as it is designed to gradually release the active ingredient over an extended period.

Q: Does Matrix affect blood pressure or heart rate?

Regulatory documents describe a risk of worsening or new onset hypertension (high blood pressure) for users of the drug. The label highlights the documented risk of serious cardiovascular thrombotic events, which includes events like heart attack and stroke.

Q: What are the ingredients in Matrix besides the active one?

The formulation contains the active ingredient Ibuprofen and various non-active components known as pharmaceutical excipients. These excipients are necessary to create the sustained-release matrix system that controls the drug's release rate. The full list of excipients is published in the official labeling.

Q: What is the difference between the immediate-release and extended-release forms of Matrix?

The key distinction is the dosing schedule determined by the release mechanism. The sustained-release formulation is administered once every 12 hours to maintain consistent levels, whereas immediate-release formulations typically require more frequent dosing.

Q: What happens to Matrix in the body (metabolism)?

Once administered, the active ingredient, Ibuprofen, is primarily processed or metabolized by the liver, involving an enzyme pathway known as CYP2C9. The resulting compounds are then largely eliminated from the body by the kidneys.

Q: What kind of monitoring (e.g., blood tests) might be needed while on Matrix?

Official documents indicate that patients with pre-existing conditions like hepatic (liver) or renal (kidney) impairment may require close monitoring. This typically involves periodic assessment of liver function and kidney function through blood tests.

Q: How quickly should I expect to feel the effects of Matrix?

Clinical pharmacology studies describe the drug's profile as having a sustained-release characteristic. While the onset of symptomatic change is typically observed within a few hours, the design is intended to maintain the therapeutic effect over the full 12-hour dosing interval.

Q: What happens if I miss a dose of Matrix?

Official patient information generally suggests that if a dose is missed, it may be taken as soon as possible unless the time for the next scheduled dose is approaching. If the next dose is due soon, the user should skip the missed dose and resume the regular schedule. Regulatory guidance states that two doses should not be taken close together.

Q: Is it normal to feel tired when starting Matrix?

Regulatory safety documents classify drowsiness and fatigue as potential side effects associated with the drug. While this occurs, these effects are typically documented as uncommon based on clinical trial data.

Q: Does taking Matrix affect my ability to drive or operate machinery?

The official label advises that because the medicine may cause effects such as dizziness or fatigue, users should remain cautious when performing skilled tasks like driving or operating machinery. Users should wait until they know how the medication affects them.

Q: Is Matrix a controlled substance or addictive?

Regulatory authorities define the active ingredient, Ibuprofen, as not a controlled substance. Official documents report no evidence of a risk for physical dependence or addiction associated with the medicine.

Q: Can Matrix be used for conditions other than what it is officially approved for?

Official authorization defines the conditions for which the drug has been reviewed and approved, known as Indications. Use of the medicine is limited to these authorized indications as described in the official label.

Q: What should I do if the medicine doesn't seem to be working after a few weeks?

The official label for certain conditions advises that if the desired symptomatic benefit is not achieved after a defined period of treatment, official documents indicate that the patient’s treatment plan may warrant review by a healthcare professional.

Q: Why is Matrix sometimes stopped suddenly, and is that safe?

The medicine is intended for short-term use, as guided by regulatory principle. Due to its pharmacological class (NSAID), there is no official warning against suddenly stopping the use of the medicine, particularly after short-term use.

Q: What does it mean if an official document says Matrix has a 'Black Box Warning'?

The Boxed Warning (often called a 'Black Box Warning') is a formal safety communication from regulatory bodies like the FDA. It is used to highlight serious safety risks, such as the documented potential for serious cardiovascular events and gastrointestinal bleeding associated with the drug class.

Q: Can I take herbal supplements like St. John's Wort with Matrix?

Official regulatory documents do not specify interactions for all individual herbal products. Patients are generally directed to remain cautious when combining the medicine with any unmonitored herbal preparations or supplements that may affect bleeding or metabolism.

Q: Is there a risk of withdrawal symptoms when stopping Matrix?

Official regulatory documentation indicates that the active ingredient, Ibuprofen, does not cause physical dependence and is not associated with withdrawal symptoms upon stopping treatment.

Q: Does Matrix cause weight gain or loss?

Regulatory documents list weight changes (either gain or loss) as a documented, though typically infrequent, adverse reaction associated with the medicine.

Q: Are there any gender-specific considerations for using Matrix?

Official documents include specific considerations for pregnancy and lactation. The pharmacokinetics section of the label may also describe any observed differences in metabolism between male and female populations.

Q: Are headaches a common side effect of Matrix?

Headache is listed in official safety documents as a documented side effect of the medicine. Based on clinical trial reporting, this effect is generally classified as uncommon.

Q: Does Matrix interact with common cold or allergy medications?

Cold and allergy medications often contain ingredients, such as other NSAIDs or Aspirin, which are formally contraindicated for use with this medicine due to an additive risk. It is important for users to verify the active ingredients of such products.

Q: How long does Matrix stay in your system after stopping treatment?

The time the drug remains in the body is characterized by its elimination half-life, which is a key pharmacokinetic parameter cited in the official clinical pharmacology section. The half-life for Ibuprofen is generally short.

Q: Can Matrix cause skin reactions or rashes?

Regulatory labels document the possibility of a skin rash as an adverse event. Authorities also specifically highlight the potential for rare, serious skin reactions such as Stevens-Johnson Syndrome (SJS), which is a critical safety warning.

Q: Why are there different versions of Matrix with different dosages?

Dosage strengths are defined to provide the appropriate amounts of the active ingredient to achieve the required therapeutic effect. This system allows prescribers to adhere to the principle of administering the lowest effective dose for each patient.

Q: What if I accidentally took too much Matrix?

Official documents describe the expected signs of overdose, which can include nausea, vomiting, dizziness, and potential central nervous system effects. The regulatory guidelines recommend seeking immediate medical intervention in the event of an accidental overdose.

Q: Can Matrix interact with common supplements like multivitamins?

Official documents do not specify any known clinical interaction risks between the active ingredient and standard multivitamin preparations. Caution is generally warranted when combining prescription medicines with any unmonitored supplements.

How to Store and Dispose of Matrix

The storage and disposal of Matrix (Ibuprofen sustained-release tablet) must strictly follow regulatory labeling to ensure product stability and safety.

Storage Conditions

Matrix must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The tablets must be protected from moisture and excessive heat. Keep the medication in the container it came in and ensure the container remains tightly closed.

Child Safety and Disposal

Store Matrix out of the sight and reach of children and pets. Unused or expired tablets should not be flushed down the toilet. Dispose of the medication using a drug take-back program or by mixing the product with an unappealing substance and sealing it for disposal in the household trash, as specified by official regulatory guidelines.